摩根士丹利发表研报指,已更新中国中药(00570.HK) 风险回报评级,在其2025年初步业绩公告后,基于预期销售额与毛利率下调,将2026至2030年的盈利预测下调5%至12%。其目标价及悲观假设估值相应下调7%;目标价由1.5元下调至1.4元;评级“减持”。(hc/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-01-27 16:25。)AASTOCKS新闻
Source Link摩根士丹利发表研报指,已更新中国中药(00570.HK) 风险回报评级,在其2025年初步业绩公告后,基于预期销售额与毛利率下调,将2026至2030年的盈利预测下调5%至12%。其目标价及悲观假设估值相应下调7%;目标价由1.5元下调至1.4元;评级“减持”。(hc/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-01-27 16:25。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.